Heart failure & cardiomyopathiesRandomised controlled trial
Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension
- Randomised controlled trial
- multicentre
Authors' conclusion
Among patients with pulmonary hypertension associated with left heart disease and heart failure receiving guideline-directed medical therapy, pulmonary-artery denervation resulted in fewer events of clinical worsening than medical therapy.
Study context
- Population
- Patients with pulmonary hypertension associated with left heart disease and HF, China
- Participants
- 264 patients
- Comparison
- Pulmonary-artery denervation vs Medical therapy
- Pulmonary-artery denervationn = 134
- Medical therapyn = 130reference
- Primary endpoint
- Clinical worsening (composite of death, heart or lung transplantation, hospitalization for HF, outpatient worsening of HF, or decline in 6-minute walk distance)
- Follow-up
- Through the latest
Primary result
As reported in the abstract
Clinical worsening, Kaplan-Meier estimated 2-year incidence · median follow-up 338 days
Hazard ratio
0.49
95% CI 0.30–0.82
P = 0.006
By group
Pulmonary-artery denervation vs Medical therapy
HR 0.49 (95% CI 0.30–0.82); P = 0.006
Safety
events
| Outcome | Pulmonary-artery denervation | Medical therapy |
|---|---|---|
| Access-site hematoma | 2 | 1 |
Access-site hematoma
- No other procedural complications
Adverse events during follow-up
- Similar frequency in the two groups
Original publication
Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension. N Engl J Med. Published 30 August 2026. doi:10.1056/nejmoa2609056
Summarised from the published abstract; every number is checked against it